Kenneth Ellsworth

Title: Kenneth Ellsworth: Innovator in Coagulation Research

Introduction

Kenneth Ellsworth is a notable inventor based in Cranbury, NJ (US), recognized for his contributions to the field of coagulation research. With a total of 9 patents, Ellsworth has made significant strides in developing innovative solutions for medical challenges related to blood coagulation.

Latest Patents

Among his latest patents, Ellsworth has developed Factor XI activation inhibitors. This invention provides a compound of Formula (I) and pharmaceutical compositions that comprise one or more of these compounds. The methods for using these compounds aim to treat or prevent thromboses, embolisms, hypercoagulability, or fibrotic changes. These compounds are specifically designed as selective Factor XI activation inhibitors. Additionally, he has patented anti-coagulation factor XI antibodies. These antibodies bind to the apple 3 domain of human coagulation Factor XI and inhibit its activation by coagulation factor XIIa, as well as the activation of FIX by FXIa.

Career Highlights

Throughout his career, Kenneth Ellsworth has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Adimab, LLC. His work in these organizations has allowed him to contribute to groundbreaking research and development in the field of coagulation.

Collaborations

Ellsworth has collaborated with notable professionals in his field, including Zhu Chen and James Milligan. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Kenneth Ellsworth's work in coagulation research has led to significant advancements in medical treatments. His innovative patents and collaborations reflect his dedication to improving healthcare outcomes.